"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...

In a state where the obesity rate ranks among the highest in the country, many were thrilled when Medicaid began covering GLP ...

Already-scarce Medicaid coverage of the highly touted weight loss drugs could become more limited, with federal Medicaid funding cuts expected in the wake of the massive tax-and-spending bill ...

Key Points Chesapeake sold 9,875 Eli Lilly and Company shares; estimated trade value of approximately $7.68 million, based on the average price for Q2 2025 Transaction represented 6.9% of fund AUM.

Rhode Island’s Medicaid program is contemplating an end to coverage for GLP-1 drugs prescribed for weight loss. The proposal ...

Eli Lilly and Co on Tuesday aimed to ease investor concerns about its COVID-19 antibody treatment after a trial of the therapy failed to show a benefit in hospitalized patients.

On Monday, Eli Lilly said it would invest $1 billion into India over the next few years to expand contract manufacturing.

NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.

Biohacker Bryan Johnson has revealed he 'microdosed' weight-loss medications, despite having under 10 percent body fat. The ...

Strong sector performers stand out as AAPL, LLY, and V gain traction through services, drug demand, and digital payment ...

Few differences were found for cardiovascular, kidney, and mortality outcomes between liraglutide, semaglutide, and dulaglutide for patients with type 2 diabetes.

High costs are a common worry among users of Ozempic, Mounjaro and other weight-loss drugs, who report varying levels of ...